RxDoctor Payments Data

Bindu Jayavelu, MD

Nephrology · Mesa, AZNPI 1003965278

Payments from drug & device makers

$3,598in general payments, 2019–2025

Across 154 payments — averaging $23.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vantive US Healthcare LLC$709
  • Otsuka America Pharmaceutical, Inc.$572
  • Amgen$522
  • AstraZeneca$460
  • Akebia Therapeutics Inc$163
  • Baxter Healthcare$144
  • plus $1K from 18 others

What the payments were for

  • Travel & lodging$46013%
  • Food & beverage$2,82078%
  • Education$3179%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,598 in reported general payments places this provider in the 60th percentile of 259 nephrology providers in Arizona.

See all nephrology providers in Arizona

Medicare billing

Part B allowed, 2024
$332,058
Medicare patients
632
Services billed
3,875

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol92$115,794
Lanthanum Carbonate22$32,462
KerendiaFinerenone22$26,432
VelphoroSucroferric Oxyhydroxide12$25,965
LokelmaSodium Zirconium Cyclosilicate35$25,377
JardianceEmpagliflozin14$19,557
Sevelamer Carbonate75$14,770
Calcitriol289$5,282
Calcium Acetate48$2,894
Cyclosporine13$2,784
Febuxostat11$2,334
Losartan Potassium211$2,152
Hydralazine Hcl79$1,532
Potassium Chloride68$1,528
Nifedipine ErNifedipine48$1,374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$460$141,171127 claims
BayerKerendia$77$26,43222 claims
Boehringer IngelheimJardiance$31$19,55714 claims
ANI Pharmaceuticals, Inc.Valsartan$17$45317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 259 nephrology providers in Arizona.

Other nephrology in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →